Retrospective, comparative, interventional, randomized, single-center study, contralateral (the patient's 2 eyes will be implanted: 1 CPO and the other APO) Patients presenting for cataract surgery with a request for presbyopia correction and managed as part of routine clinical practice.
The main aim of the study is to demonstrate that contrast sensitivity is better with the Clareon PanOptix (CPO) intraocular lens (IOL) compared with the AcrySof PanOptix (APO) IOL 3 months after implantation.
Patients ≥ 18 years of age
Patients presenting for cataract surgery in routine clinical practice and eligible for multifocal IOL implantation (toric and non-toric)
Patients with grade 2/3 cataract density and comparable visual acuity in both eyes
Patient with a pregnancy test (negative pregnancy test), if applicable
Children < 18 years of age
Pregnancy or breast-feeding in progress or planned during the study.
History of anterior (cornea, anterior chamber, sulcus) or posterior (uveal, vitreoretinal) segment pathology, including retinal vascular occlusive disease, retinal detachment or peripheral retinal laser photocoagulation, AMD, glaucoma.
Any inflammation of the anterior or posterior segment, whatever the etiology, and/or history of any disease with intraocular inflammatory repercussions.
Assistance Publique - Hôpitaux de Paris
Lead sponsor
Alcon Research
Collaborator
URC-CIC Paris Descartes Necker Cochin
Collaborator